Voya Investment Management LLC lowered its stake in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 1.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 267,834 shares of the biopharmaceutical company’s stock after selling 2,642 shares during the period. Voya Investment Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $11,458,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. First Mercantile Trust Co. grew its holdings in Ultragenyx Pharmaceutical by 16.9% during the second quarter. First Mercantile Trust Co. now owns 1,151 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 166 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Ultragenyx Pharmaceutical by 6.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 212 shares during the period. United Services Automobile Association lifted its holdings in Ultragenyx Pharmaceutical by 0.7% in the second quarter. United Services Automobile Association now owns 31,483 shares of the biopharmaceutical company’s stock valued at $1,999,000 after acquiring an additional 215 shares during the period. Smith Asset Management Group LP lifted its holdings in Ultragenyx Pharmaceutical by 22.6% in the second quarter. Smith Asset Management Group LP now owns 1,680 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 310 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in Ultragenyx Pharmaceutical by 0.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 40,005 shares of the biopharmaceutical company’s stock worth $1,712,000 after purchasing an additional 332 shares in the last quarter.

In related news, CEO Emil D. Kakkis purchased 5,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, September 11th. The stock was bought at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the acquisition, the chief executive officer now directly owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.80% of the company’s stock.

RARE opened at $41.56 on Wednesday. The firm has a market cap of $2.29 billion, a PE ratio of -5.62 and a beta of 2.16. Ultragenyx Pharmaceutical Inc has a twelve month low of $35.41 and a twelve month high of $74.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.64 and a current ratio of 6.79. The firm’s fifty day moving average is $39.77 and its two-hundred day moving average is $51.22.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.71) by ($0.25). The business had revenue of $25.80 million for the quarter, compared to the consensus estimate of $28.88 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 119.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.74) earnings per share. Equities analysts forecast that Ultragenyx Pharmaceutical Inc will post -7.28 EPS for the current fiscal year.

Several equities analysts have recently weighed in on RARE shares. ValuEngine lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Piper Jaffray Companies set a $75.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, September 4th. Leerink Swann restated a “positive” rating and set a $85.00 target price (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $75.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, Morgan Stanley cut their price objective on Ultragenyx Pharmaceutical from $79.00 to $76.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Ultragenyx Pharmaceutical has an average rating of “Buy” and an average target price of $73.33.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Article: Google Finance Portfolio Workaround

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.